By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.

The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.

The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.

The appropriations package would boost the NIH's fiscal 2019 budget to $39.1 billion, and earmarks money for programs such as the All of Us initiative.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

➢ Human induced pluripotent stem cell (iPSC) technology has provided unique ways to understand and
potentially treat human diseases using cells from individual patients.
➢ iPS cells are amenable to genomic modifications using site-specific gene editing technologies such as
CRISPR/Cas9, by which we can correct/ introduce precise disease causing mutations in patient or healthy
iPSCs, respectively.
➢ Genome edited iPSCs and their isogenic control (or parental line) offer highly-controlled experimental models
for reliable comparison of results.

The goal of this experiment was to utilize the Echo 525 Liquid Handler in assembling five, five-piece assemblies by substituting modular DNA pieces at the nanoliter scale. The Labcyte Echo Liquid Handler enables lower-cost methods and workflows to produce high-quality synthetic DNA constructs.

Introduction to In Vivo Probe Validation:

Before beginning a large animal study, it is critical to confirm that your labeled targeting agent is specific to the intended target within the biological complexity of the whole animal. Understanding the biodistribution and clearance of a labeled targeting agent is critical for meaningful image analysis and interpretation. This guide will provide an overview of how to validate a targeting agent in vivo.